Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer

NCT03258034 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhejiang Chinese Medical University as lead sponsor.

NCT NCT03258034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03258034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
August 24, 2017
Completion date
October 22, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer